What if you invested $1000 in REGN on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 20 years, Regeneron Pharmaceuticals, Inc. has delivered an average annual return of 27.1%. The stock peaked in 2012 with a massive +203.2% gain, while investors faced a downturn in 2016 (-28.9%). Overall, the stock finished in the green 15 times out of 20 years.
Avg Return
+27.1%
Win Rate
75%
15W - 5L
Best
+203.2%
2012
Worst
-28.9%
2016
Performance Consistency
About Regeneron Pharmaceuticals, Inc.
Visit Website ↗Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Its medicines target eye diseases, allergic and inflammatory diseases, cancer, and more.
Key Business Segments
Pharmaceuticals
Eylea, Dupixent, Libtayo.
Key Innovations
- ✓VelocImmune® technology (human antibody generation)
- ✓Regeneron Genetics Center
Historical Milestones
Founded by Leonard Schleifer.
IPO on NASDAQ.
FDA approval of Eylea.